Founded in Bangalore, India. $6Mio seed funding by Accel, Aarin, IDG, KITVEN
Development of technology platforms. Glyco-Engineering. Naïve & Synthetic Display Libraries. Development of trastuzumab biosimilar and Exendin-4.
Zumutor incorporated in USA with ofﬁce in MA. Series A $6 Mio raised from existing investors. Global patents filed.
Research collaboration signed with global major, Catalent, for ADCC enhancement
Ideation and selection. 21 immunotherapy targets chosen.
In vivo efficacy study with lead molecule initiated. Out licensed Trastuzumab biosimilar.
Mouse study reveals signﬁcant reduction in tumour growth compared to “Control IgG”.
Raised $ 4 Mio from Accel for preclinical studies
At Zumutor , we have developed two antibody engineering platforms to facilitate our program for discovery and development of immunotherapies that have the potential to be novel best-in-class monotherapies, and core components of innovative combination treatments.
We are committed to partnering with global biopharmaceutical companies for early stage licensing of our pipeline and to jointly discover and develop innovative products.
We have licensed our biologic product for treatment of breast cancer and are engaged in collaborations and related to our technology platforms.
For additional information on partnering with Zumutor, please contact our business development team at email@example.com
We have committed our resources to develop treatment of cancer through next generation immunotherapies and have assembled a highly experienced team to execute our vision
OUR SCIENTIFIC ADVISORS
OUR STRATEGIC ADVISORS
Our VC Partners
We have raised a US$ 16 million in capital from Accel Partners, IDG ventures, Aarin Capital and KITVEN
Discover The Future
We attract, retain and nurture scientific talent that shares our dream of pushing the boundaries of therapeutic research. We believe in innovation and a science-based approach.